US Patent
US7579449 — Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Composition of Matter · Assigned to Boehringer Ingelheim International GmbH · Expires 2028-08-01 · 2y remaining
Vulnerability score
17/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects glucopyranosyl-substituted benzene derivatives and their salts, which are suitable for treating metabolic disorders.
USPTO Abstract
Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.